乙型肝炎病毒阿德福韦酯耐药相关变异的研究进展  

Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus

作　　者：叶晓玲[1] 刘妍[1] 徐东平[1] 

机构地区：[1]解放军第302医院肝衰竭诊疗与研究中心/传染病研究所病毒性肝炎研究室,北京100039

出　　处：《实用肝脏病杂志》2015年第3期312-316,共5页Journal of Practical Hepatology

基　　金：北京市然科学基金面上项目(7132224);国家自然科学基金面上项目(81371852)

摘　　要：目前口服核苷酸类似物阿德福韦酯(adefovir dipivoxil,ADV)仍是我国临床治疗慢性乙型肝炎(chronic hepatitis B,CHB)的主要抗病毒药物之一。但是,长期服用ADV可能导致乙型肝炎病毒(hepatitis B virus,HBV)产生耐药变异。经典的ADV耐药变异形式为rt A181V和rt N236T,新鉴定的ADV原发耐药变异为rt A181S、rt E218G和rt N236V。此外,rt A181T、rt V214A、rt Q215H/P/S、rt L217R/P、rt I233V和rt N238T/D/H等位点变异与HBV对ADV耐药仍存在争议,尚需进一步明确。Adefovir dipivoxil （ADV）,an oral nucleotide analogue,remains as one of the major antiviral agents in the treat- ment of chronic hepatitis B（CHB） in China. However,long-term therapy with ADV may lead to hepatitis B virus（HBV） drug-re- sistant mutations. The signature mutations associated with ADV resistance are rtA181V and rtN236T. The newly-identified ADV primary resistant mutations are rtA181S,rtE218G and rtN236V. In addition,some other mutations including rtA181T,rtV214A, rtQ215H/P/S,rtL217R/P,rtI233V,and rtN238T/D/H remain contradictory,and these mutations need to be further identified.

关 键 词：乙型肝炎病毒 阿德福韦酯 耐药 基因变异 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]